Researchers at Tel Aviv University (TAU) discovered a new factor in the pathology of Parkinson's disease, which in the future ...

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has ...

AC Immune (ACIU) stock shot up 20% Thursday after the company reported positive data from a Phase 2 study of its drug ...

Analysis suggests that the research and development of DMTs and non-motor therapies will diversify Parkinson's treatment ...

There has been a lot of excitement since the launch. Not only is the drug extremely effective (people lose about 15 percent ...

Researchers at Tel Aviv University (TAU) discovered a new factor in the pathology of Parkinson's disease, which in the future ...

AC Immune SA (ACIU) has released an update. AC Immune SA announced promising interim results from its Phase 2 trial of the ACI-7104.056 ...

With rising demand and an ageing population, European healthcare systems are under strain. In the second article in our ...

reinforces the best-in-class characteristics of our clinically validated anti-a-syn active immunotherapy for the treatment of ...

Israeli scientists have identified a promising new factor in the pathology of Parkinson’s disease that could pave the way for ...

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has identified a potential biomarker of Parkinson's disease progression.